For the selected key target gene VEGFA, on the one hand, relevant experiments have proved that decreased levels of VEGFA in serum and cerebrospinal fluid are linked with increased risk for AD and cognitive impairments [58,59], while on the other hand, it has been reported that EGCG could inhibit wild-type EGFR as well as some of its mutated forms [60]. This evidence concerns the gene EGFR and Alzheimer disease.